Immune checkpoint inhibitors in GBM

Area of Science:

• Neuro-oncology
• Immunotherapy
• Cancer Research

Background:

• Glioblastoma (GBM) remains a challenging brain cancer with poor prognosis.
• Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but show limited efficacy in GBM.
• Understanding brain immunology and resistance mechanisms is crucial for improving GBM treatment.

Purpose of the Study:

• To review recent advancements in immune checkpoint inhibitor (ICI) therapy for glioblastoma (GBM).
• To cover updates in brain immunology, clinical trials, resistance mechanisms, and biomarkers for GBM patients receiving ICIs.

Main Methods:

• A comprehensive literature search of PubMed was conducted for relevant articles on ICI therapy in GBM.
• Clinicaltrials.gov was searched to identify ongoing and completed clinical trials related to ICIs in GBM.

Main Results:

• Randomized phase 2 and 3 clinical trials of ICIs in GBM (newly diagnosed or recurrent) have not yet shown a significant survival benefit.
• A preliminary study suggested potential benefits of neoadjuvant/adjuvant pembrolizumab, requiring further validation.
• Response rates to ICIs in GBM patients are generally low.

Conclusions:

• Only a small fraction of glioblastoma patients benefit from current immune checkpoint inhibitor therapies.
• Identifying predictive biomarkers of response is essential for patient selection.
• Developing rational combination strategies with ICIs is necessary to enhance treatment efficacy in GBM.